You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up
|
|---|---|
| Published in |
Targeted Oncology, July 2019
|
| DOI | 10.1007/s11523-019-00658-0 |
| Pubmed ID | |
| Authors |
Anna W. Chalmers, Shiven Patel, Ken Boucher, Laura Cannon, Michelle Esplin, Julie Luckart, Natalie Graves, Terry Van Duren, Wallace Akerley |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 20% |
| Norway | 1 | 20% |
| United States | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 51 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 10% |
| Other | 4 | 8% |
| Student > Doctoral Student | 4 | 8% |
| Student > Ph. D. Student | 4 | 8% |
| Student > Bachelor | 3 | 6% |
| Other | 9 | 18% |
| Unknown | 22 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 27% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Engineering | 2 | 4% |
| Nursing and Health Professions | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 24 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 October 2019.
All research outputs
#13,963,083
of 24,076,257 outputs
Outputs from Targeted Oncology
#191
of 573 outputs
Outputs of similar age
#168,472
of 349,568 outputs
Outputs of similar age from Targeted Oncology
#5
of 17 outputs
Altmetric has tracked 24,076,257 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 573 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 349,568 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.